Abrysvo (PF-06928316) / Pfizer - LARVOL DELTA

Targeting premature ageing of the immune system in dialysis patients (TTS 2026) - "This study aims to evaluate response to Shingrix and RSV vaccine responses in hemodialysis patients, identify age-associated immunological markers that predict impaired responses... If age-associated immunosenescence and inflammageing are identified as risk factors for vaccine hyporesponsiveness, sirolimus will be investigated as a treatment to improve vaccine responses in a randomized controlled trial."

Clinical • Herpes Zoster • Infectious Disease • Influenza • Renal Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IFNG

Maternal RSV vaccination: clinical efficacy, safety, and global policy considerations: a systematic review. (PubMed, J Pharm Policy Pract) - "Real-world data from a variety of situations now supports the conclusion that maternal RSV vaccination consistently decreased newborn RSV hospitalisation and severe disease. However, ongoing post-marketing surveillance and formulation-specific safety reporting are necessary due to variations in preterm birth risk that rely on timing and formulation."

Journal • Review • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Respiratory Syncytial Virus Vaccine Effectiveness Among US Older Adults, 2023-2024 Season. (PubMed, JAMA Netw Open) - "RSV vaccines demonstrated substantial effectiveness within this high-risk older adult population, including among immunocompromised individuals and across all ages 65 years or older. This large postmarketing noninterventional study provides clinical evidence of RSV vaccine effectiveness in the first year of vaccine approval."

Journal • Retrospective data • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Construction and application of a novel respiratory syncytial virus vaccine based on Bacteroides thetaiotaomicron outer membrane vesicles. (PubMed, Front Microbiol) - "For instance, Abrysvo and Arexvy pose potential safety risks in clinical use, and the long-term protective efficacy of mRESVIA may wane over time...This strategy capitalizes on the unique advantages of Bt OMVs, including efficient mucosal delivery, low inherent toxicity, and targeted modulation of T cell homeostasis-specifically enhancing Treg and Th1 responses while suppressing excessive Th2 and Th17 activation, which serves as the core mechanism for preventing vaccine-enhanced disease (VED)-to effectively present the RSV F protein antigen. It offers a novel approach to develop next-generation RSV vaccines that combine durable protection with enhanced clinical safety."

Journal • Review • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Bivalent RSVpreF Effectiveness Against Respiratory Syncytial Virus (RSV)-Related Respiratory Disease Hospitalization and Emergency Department Visits Across Three RSV Seasons. (PubMed, Infect Dis Ther) - P | "Bivalent RSVpreF provides protection against RSV-related respiratory hospitalization/ED visits for at least three seasons after vaccination in this population of older adults with a high prevalence of comorbidities. Estimates in the third season for ARI were more definitive, while those for LRTD were imprecise due to limited event numbers. This suggests bivalent RSVpreF vaccination results in substantial individual and public health benefit."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Real-world Abrysvo Vaccine Effectiveness (VE) against RSV-Associated Lower Respiratory Tract Disease (LRTD) Hospitalizations and Emergency Department Admissions among Patients with High-Risk Comorbidities over Two RSV Seasons—Kaiser Permanente of Southern California (KPSC), October 2023–April 2025 (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease • Respiratory Syncytial Virus Infections

Real-World Evidence on the Effectiveness of Maternal RSVpreF Vaccination: A Living Systematic Review and Meta-Analysis (IDWeek 2026) - No abstract available

HEOR • Real-world • Real-world evidence • Retrospective data • Review • Infectious Disease

Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus (RSV) in Hospitalized Infants by Age, Vaccination Characteristics, and RSV Subtype: A Multicenter Test-Negative Design Study in Australia, 2025-2026 (STREETON Study) (IDWeek 2026) - No abstract available

Clinical • Infectious Disease • Respiratory Syncytial Virus Infections

A Study to Learn About the Safety and Immune Responses of RSVpreF in Older Adults (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Pfizer

New P3 trial • Respiratory Diseases • Respiratory Syncytial Virus Infections

Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile. (PubMed, Expert Rev Vaccines) - "At a threshold of CLP15,977,348 (US$17,180) per QALY gained, the maximum cost-effective vaccine price was CLP100,480 (US$108) and CLP265,261 (US$285) from the healthcare and societal perspectives respectively. RSVpreF vaccination would reduce RSV burden and likely be cost-effective for older adults in Chile."

HEOR • Journal • Geriatric Disorders • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults (clinicaltrials.gov) - P3 | N=440 | Recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Recruiting

Enrollment open • Respiratory Diseases • Respiratory Syncytial Virus Infections

RSV vaccine for preventing respiratory and cardiovascular hospitalizations in heart failure: a prespecified analysis of the extended DAN-RSV trial. (PubMed, Eur J Heart Fail) - P4 | "Trial registration NCT06684743, registered 9 November 2024 (https://clinicaltrials.gov/study/NCT06684743)."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Respiratory Syncytial Virus Infections

Durability of RSV Prefusion F Vaccine Protection across Two RSV Seasons. (PubMed, NEJM Evid) - P4 | "Among adults 60 years of age or older, the RSVpreF vaccine was associated with a lower incidence of RSV-related respiratory tract disease during a second RSV season as compared to no vaccine. Vaccine effectiveness estimates appeared to be lower in the second season compared to the first. (Funded by Pfizer; ClinicalTrials.gov number, NCT06684743.)."

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults. (PubMed, NEJM Evid) - P4 | "In a randomized trial that included expanded demographic and geographic enrollment during a second RSV season, the RSVpreF vaccine was associated with a lower incidence of RSV-related respiratory tract disease hospitalization as compared to no vaccine. (Funded by Pfizer; ClinicalTrials.gov number, NCT06684743.)."

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections

Risk of Myocarditis and Pericarditis With Bivalent RSV Prefusion F Protein-Based Vaccine: A Safety Analysis of the Extended DAN-RSV Trial. (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiovascular • Inflammation • Respiratory Diseases • Respiratory Syncytial Virus Infections

Cost-Effectiveness Analysis of Older Adult Vaccination with the Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccine in Mexico. (PubMed, Vaccines (Basel)) - "Year-round RSVpreF vaccination in Mexico among adults aged 60-99 years could substantially reduce medically attended RSV cases and RSV-related mortality and is projected to be cost-effective, thereby supporting the adoption of preventive strategies to address the growing clinical and economic burden of RSV in Mexico's aging population."

HEOR • Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections

A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention. (PubMed, Trop Dis Travel Med Vaccines) - "Until now, three RSV vaccines, Arexvy, Abrysvo, and mRESVIA, have received approval from the FDA. In addition, monoclonal antibodies such as Nirsevimab and Clesrovimab prevent severe RSV disease and are recommended for infants. Given the significant global impact of RSV, this narrative review addresses its multifaceted aspects, including epidemiology and global impact, clinical manifestations, therapeutic strategies, vaccine development, and its emerging potential as an oncolytic agent."

Journal • Review • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Regional, altitudinal, and age-specific heterogeneity of bronchiolitis hospitalization seasonality in Ecuador, 2007-2024, and implications for RSV immunoprophylaxis timing. (PubMed, Front Public Health) - "Bronchiolitis seasonality in Ecuador changed after the pandemic, most clearly and stably in Costa; Sierra showed a transient 2022 perturbation with partial reversion by 2023-2024, and Amazonía's estimates remained unstable and underpowered. As region-tailored estimates are less stable in Sierra and Amazonía than in Costa, a single national window (nirsevimab February-April; maternal RSVpreF for pregnancies expected to deliver January-May) is a more defensible starting point, pending confirmation from further seasons and, ideally, laboratory-confirmed surveillance."

Heterogeneity • Journal • Gastroenterology • Gastrointestinal Disorder • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance to protect infants and children from respiratory syncytial virus disease. (PubMed, Can Commun Dis Rep) - "In March 2026, the National Advisory Committee on Immunization (NACI) released updated guidance reflecting new evidence on the monoclonal antibodies (mAbs) nirsevimab (Beyfortus®) and clesrovimab (Enflosia) and the RSVpreF pregnancy vaccine (Abrysvo)...At current product list prices, the combined pregnancy-infant program offers better value than a universal mAb program. Jurisdictions should consider local epidemiology, feasibility, cost-effectiveness considerations and equity when selecting a program model."

Journal • Critical care • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT. (PubMed, Vaccine) - "This is the first cost-effectiveness model to describe the public health impact of alternative vaccination strategies for RSV prevention in France. The number of hospitalizations avoided ranged from 7,600 stays in the recommended strategy, to more than 13,000 in the year-round strategy, corresponding to hospital savings between €24.7 million and €41.5 million. Alternative scenarios were shown to extend prevention to older age groups. Broader vaccination strategies, notably the extended strategy, had a positive impact on RSV hospital burden, with a limited impact on total costs."

HEOR • Journal • Infectious Disease • Pediatrics • Respiratory Diseases • Respiratory Syncytial Virus Infections

Temporal and disproportionality analysis of vaccine-associated Guillain-Barré syndrome: a 21-year VAERS study. (PubMed, Front Neurol) - "Novel signals emerged for both RSV vaccines (Arexvy ROR 3.01, Abrysvo ROR 6.82) and zoster vaccine (ROR 3.01), consistent with post-marketing estimates of 3-9 excess cases per million doses...Multiple vaccines showed disproportionate GBS reporting signals with delayed temporal patterns consistent with biological plausibility; because these derive from passive surveillance, they are hypothesis-generating and do not establish causality. Despite rare associations, absolute risks (1-9 per million doses) are far outweighed by disease prevention benefits, supporting current vaccination policies with ongoing surveillance."

Journal • Herpes Zoster • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

Comparison chart: Some vaccines for adults. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus

A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults (clinicaltrials.gov) - P3 | N=440 | Not yet recruiting | Sponsor: Pfizer

New P3 trial • Respiratory Diseases • Respiratory Syncytial Virus Infections

Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants. (PubMed, JAMA Pediatr) - "Findings in this case-control study demonstrate high year-round effectiveness of RSVpreF vaccination against RSV-associated hospitalization in infants 6 months of age or younger in the first year following introduction in Australia, with the highest VE observed in the earliest age intervals. Future analyses with larger sample sizes will evaluate VE among additional subgroups."

Journal • Respiratory Diseases • Respiratory Syncytial Virus Infections